Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Assets (2022 - 2025)

Historic Return on Assets for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to 0.24%.

  • Entrada Therapeutics' Return on Assets fell 3400.0% to 0.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.24%, marking a year-over-year decrease of 3400.0%. This contributed to the annual value of 0.13% for FY2024, which is 1500.0% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Return on Assets of 0.24% as of Q3 2025, which was down 3400.0% from 0.16% recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Return on Assets registered a high of 0.19% during Q2 2024, and its lowest value of 0.36% during Q4 2022.
  • Its 4-year average for Return on Assets is 0.06%, with a median of 0.03% in 2023.
  • As far as peak fluctuations go, Entrada Therapeutics' Return on Assets skyrocketed by 3600bps in 2024, and later plummeted by -3500bps in 2025.
  • Over the past 4 years, Entrada Therapeutics' Return on Assets (Quarter) stood at 0.36% in 2022, then surged by 96bps to 0.01% in 2023, then soared by 966bps to 0.12% in 2024, then tumbled by -298bps to 0.24% in 2025.
  • Its Return on Assets stands at 0.24% for Q3 2025, versus 0.16% for Q2 2025 and 0.05% for Q1 2025.